Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome

Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Azad, Farhan, Miranda, Clive J, Amin, Al, Hadwani, Ruhi, Gravina, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078131/
https://www.ncbi.nlm.nih.gov/pubmed/37033542
http://dx.doi.org/10.7759/cureus.35874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078131/
https://www.ncbi.nlm.nih.gov/pubmed/37033542
http://dx.doi.org/10.7759/cureus.35874

Ejemplares similares